Safety Profile
AOD-9604 Side Effects: Frequency & Severity
AOD-9604 has a favorable safety profile in Phase II human trials. It does not significantly affect IGF-1 or glucose, differentiating it from full-length GH.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Common side effects
1Injection site reactions
Mild erythema or itching.
Uncommon side effects
1Headache
Reported in clinical trials.
Rare side effects
2Nausea
Uncommon.
Fatigue
Rarely reported.
Contraindications
- Known hypersensitivity
- Pregnancy
- Active malignancy (theoretical)
Drug interactions
- Limited clinical interaction data
- Additive with other lipolytic agents theoretically possible
Special populations
Not FDA approved. Not recommended in pregnancy. Limited elderly data.
Overall safety summary
AOD-9604 has a clean safety profile in Phase II weight-loss trials. Unlike full-length GH, it does not induce insulin resistance or IGF-1 elevation.
AOD-9604 side effects: FAQ
Does AOD-9604 cause insulin resistance?
No — one of its advantages over full-length GH is that it retains lipolytic activity without affecting glucose tolerance.